Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD
Status:
Completed
Trial end date:
2017-12-15
Target enrollment:
Participant gender:
Summary
Polycystic kidney disease (ADPKD) is a common genetic disorder, characterized by the
formation of cysts in the kidneys, causing gradual renal function-loss. Previous studies have
shown that, reduced glomerular filtration rate (GFR) and renal plasma flow (RPF) play a role
in the progression of renal disease in ADPKD. Tolvaptan is a vasopressin 2 antagonist, which
seems to reduce the growth of total kidney volume (TKV) and the decline in e-GFR in ADPKD.
The mechanism is not fully understood and could, at least partly, be caused by stimulation of
the renal blood flow. The purpose of this trial is to investigate if tolvaptan´s improve
renal blood flow and glomerular filtration in ADPKD, in a randomized, cross-over,
double-blind, placebo-controlled study.